Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- Idera Pharmaceuticals, Inc.
- Study ID
- NCT03865082
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tilsotolimod — DRUG9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
- Nivolumab — DRUGSpecified dose on specified days.
- Ipilimumab — DRUGSpecified dose on specified days.
Study Details
A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.
Key Dates
- Start date
- Oct 29, 2019
- Status verified
- Feb 2022
- Primary completion
- Mar 31, 2022
- Completion
- Apr 30, 2022
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: IO Naive Subjects MSS CRC8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous
Primary Outcome Measure
Demonstrate the efficacy of intratumoral tilsotolimod in combination with ipilimumab and nivolumab for each cohort [ Time Frame: ORR defined as a CR or partial response (PR) according to RECIST v1.1, confirmed by imaging ≥ 4 weeks after the initial documentation of response (to occur up to 24 months). ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Banner University Medical Center Tucson Campus | Tucson | Arizona | 85719 | - |
| University of Southern California/ Hoag Hospital Presbyterian | Newport Beach | California | 92663 | - |
| MD Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Tucson, AZ
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of RecurrenceEARLY_PHASE1 · Recruiting · Miller Children's & Women's Hospital Long Beach · Long Beach, California
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland